Clinical Trials
56
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1636
Active, not recruiting
4
7.1%
Completed
39
69.6%
Not yet recruiting
3
5.4%
Recruiting
1
1.8%
Terminated
3
5.4%
Unknown
2
3.6%
Withdrawn
4
7.1%
No approval data available
- Harvard University agreed to pay $53 million to resolve class action lawsuits alleging negligence in its handling of donated human remains at Harvard Medical School's morgue. - Former morgue manager Cedric Lodge was sentenced to eight years in prison for stealing and selling organs, brains, faces, and other body parts from donated cadavers between 2018 and 2022. - The settlement includes a live webinar statement to families affirming Lodge's conduct was "morally reprehensible" and an annual medical student scholarship honoring anatomical donors beginning in 2027-2028. - An initial class action lawsuit estimated between 350 and 400 donated cadavers may have been affected by the misconduct.
- The fourth edition of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026) will take place from 14 to 16 September 2026 in Saudi Arabia's capital, expecting over 15,000 visitors and delegations from more than 70 countries. - The Summit is organized under Saudi Arabia's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040, with six thematic tracks spanning AI, multi-omics, investment, immunology, bioengineering, and workforce development. - More than 100 speakers and over 65 agreements and memoranda of understanding are targeted across the three days, highlighting partnerships with Harvard University, AstraZeneca, and Peking University. - Spain joins Germany, South Korea, China, the United States, and Japan as one of six selected national ecosystems featured in the International Pavilion, with complimentary exhibition space valued at approximately $44,600.
- At least 105 elite American scientists have defected to Chinese institutions since 2024, with nearly half specializing in biotechnology and medicine. - High-profile recruits include Harvard chemist Charles Lieber, Nobel laureate Omar Yaghi, and leading virologist Haitao Hu, drawn by multimillion-dollar funding and advanced laboratories. - China's government R&D spending surged 90% to $133 billion from 2013 to 2023, while the country surpassed the US in clinical trial volume in 2024. - Experts warn the talent exodus threatens US national security and competitive advantage in drug development, as scientists cite fewer regulatory restrictions in China.
- MedTherapy, funded by Tata Sons, operates as a contract development and manufacturing organization (CDMO) with facilities in Boston and New Delhi to reduce CAR-T therapy production costs and timelines. - The company has developed manufacturing platforms that can produce CAR-T therapies in one day compared to several weeks for industry standard, targeting both blood cancers and solid tumors. - MedTherapy collaborates with 22 global academic institutes including Harvard University and has partnerships with Cipla for cell and gene therapy development in India. - The company's blood cancer CAR-T therapy program has completed clinical studies in the US and is preparing for clinical trials in India, demonstrating promising response rates and safety profiles.
- Harvard University has expanded its research alliance with Northpond Labs to fund translational research across multiple schools including the Wyss Institute, Harvard Medical School, and engineering departments. - The collaboration builds on a successful 2020 partnership that led to the creation of EnPlusOne Biosciences, a startup developing enzymatic RNA synthesis platforms for next-generation RNA therapeutics. - Harvard Medical School will receive direct funding to de-risk promising therapeutic drug candidates and accelerate their progression toward clinical use. - The expanded alliance aims to transform foundational academic research into industry-defining healthcare innovations through streamlined commercialization pathways.
- The FDA has granted Fast Track designation to CS-1103, a first-in-class small molecule developed by Clear Scientific for treating acute fentanyl intoxication. - CS-1103 works by binding and encapsulating intoxicants in the blood to rapidly reverse toxic effects and accelerate clearance into urine. - The injectable therapeutic demonstrated safety and tolerability in Phase 1 trials, with Phase 2 trials for fentanyl expected to begin in June 2026. - The designation addresses a critical unmet need in the opioid crisis, which causes 2,500 emergency department visits and 150 deaths daily in the US.
- Cedars-Sinai investigators developed a blood filtering treatment that removes harmful sFlt-1 protein to manage severe early preeclampsia, a leading cause of premature birth and maternal death. - The treatment safely extended pregnancies by an average of 10 additional days in 16 women with early preeclampsia, potentially doubling the time to delivery after hospitalization. - The extracorporeal apheresis technique reduced blood sFlt-1 levels by 17 percent and slightly decreased blood pressure while allowing continued fetal growth during treatment. - Larger controlled trials are needed to confirm safety and effectiveness, as the current study's small size cannot fully address all safety concerns.
- Biossil, founded by University of Toronto alumni, has secured $70 million in funding from Peter Thiel's Founders Fund and OpenAI to revive abandoned pharmaceutical compounds using AI technology. - The company has acquired 10 failed drug molecules and advanced two into late-stage clinical trials, with three more seeking regulatory approval for market entry. - Biossil's AI platform analyzes publicly available data from failed trials to identify overlooked therapeutic opportunities, potentially saving years of development time and hundreds of millions in costs. - Two lead candidates target sickle cell disease, with one receiving Health Canada approval for late-stage trials and another seeking conditional market approval after AI revealed optimal dosing windows.
- Ternary Therapeutics raised £3.6 million in seed funding to scale its AI-powered platform for designing molecular glue drugs that force proteins to bind together for therapeutic purposes. - The London-based company combines physics-informed AI, molecular dynamics modeling, and laboratory testing to systematically design molecular glues rather than relying on accidental discovery. - The platform has already generated a preclinical pipeline targeting inflammatory diseases and secured multiple research collaborations with pharmaceutical and biotechnology companies. - Former Arvinas R&D president Dr. Ian Taylor joined Ternary's board, bringing expertise from targeted protein degradation research and six IND submissions during his tenure.
- Researchers at Harvard's Wyss Institute developed DoriVac, a DNA origami vaccine platform that functions as both vaccine and adjuvant, targeting conserved peptide regions in viral spike proteins including SARS-CoV-2, HIV, and Ebola. - In preclinical studies, DoriVac vaccines produced comparable immune responses to current mRNA vaccines while offering superior stability, easier manufacturing, and elimination of cold-chain storage requirements. - The platform demonstrated strong humoral and cellular immune activation in both mouse models and human lymph node-on-chip systems, with significantly increased numbers of antibody-producing B cells and protective T cell populations. - DoriVac vaccines present antigens and adjuvant molecules with nanometer-scale precision on self-assembling DNA nanostructures, providing unprecedented control over vaccine composition and immune cell targeting.
